In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice

Journal of the Neurological Sciences

Volumn 318, Issue 1-2, 2012, Pages 36-44

  Kandagaddala, Lakshmi Devi ^a,b,d   Kang, Min Jung ^a,b   Haque, Md Mamunul ^a,b   Im, Hye Yeon ^a   Seo, Ji Eun ^a,b   Chung, Bong Chul ^a,b   Jung, Byung Hwa ^a,b   Patterson, Tucker A ^c   Kwon, Oh Seung ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cytokines; EAE; L Leucinethiol; Mice; MMP 9; NADPH oxidase

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 5; L LEUCINETHIOL; METALLOPROTEINASE INHIBITOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LEUCINE; MICE; MICE, INBRED C57BL; NADH, NADPH OXIDOREDUCTASES; RANDOM ALLOCATION; SULFHYDRYL COMPOUNDS;

EID: 84861592807     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.04.009     Document Type: Article

References (83)

1. A. Khoruts, S.D. Miller, and M.K. Jenkins Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells J Immunol 155 1995 5011 5017
2. V.W. Yong, C.A. Krekoski, P.A. Forsyth, R. Bell, and D.R. Edwards Matrix metalloproteinases and diseases of the CNS Trends Neurosci 21 1998 75 80
3. J. Correale, and A. Villa The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting Autoimmunity 40 2007 148 160
4. K. Gijbels, S. Masure, H. Carton, and G. Opdenakker Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders J Neuroimmunol 41 1992 29 34
5. W. Bruck, and C. Stadelmann Inflammation and degeneration in multiple sclerosis Neurol Sci Suppl. 5 2003 S265 S267
6. Y. Sonobe, S. Jin, J. Wang, J. Kawanokuchi, H. Takeuchi, and T. Mizuno Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis Tohoku J Exp Med 213 2007 329 339
7. J.M. Clements, J.A. Cossins, G.M. Wells, D.J. Corkill, K. Helfrich, and L.M. Wood Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor J Neuroimmunol 74 1997 85 94
8. H.P. Hartung, and B.C. Kieseier The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system J Neuroimmunol 107 2000 140 147
9. P. Proost, J. Van Damme, and G. Opdenakker Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein Biochem Biophys Res Commun 192 1993 1175 1181
10. D. Leppert, J. Ford, G. Stabler, C. Grygar, C. Lienert, and S. Huber Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapse and stable phases of multiple sclerosis Brain 121 1998 2327 2334
11. K. Gijbels, and L. Steinman Gelatinase B producing cells in multiple sclerosis lesions J Biol Chem Suppl.18D 1994 143
12. E.N. Benveniste Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis J Mol Med 75 1997 165 173
13. R.L. Lindberg, C.J. De Groot, L. Montagne, P. Freitag, P. van der Valk, and L. Kappos The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain 124 2001 1743 1753
14. G.M. Liuzzi, M. Trojano, M. Fanelli, C. Avolio, A. Fasano, and P. Livrea Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis Mult Scler 8 2002 222 228
15. A. Weaver, A. Goncalves da Silva, R.K. Nuttall, D.R. Edwards, S.D. Shapiro, S. Rivest, and V.W. Yong An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization FASEB J 19 2005 1668 1670
16. V.W. Yong, R.K. Zabad, S. Agrawal, A. Goncalves Dasilva, and L.M. Metz Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators J Neurol Sci 259 2007 79 84
17. B. Dubois, S. Masure, U. Hurtenbach, L. Paemen, H. Heremans, and J. Van den Oord Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions J Clin Invest 104 1999 1507 1515
18. M. Hidalgo, and S.G. Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178 193
19. 2) increases the steadystate mRNA levels of collagenase/MMP-1 in human dermal fibroblasts Free Radic Biol Med 22 1997 515 524
20. K. Grote, I. Flach, M. Luchtefeld, E. Akin, S.M. Holland, and H. Drexler Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species Circ Res 92 2003 e80 e86
21. S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, and Z.S. Galis Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability J Clin Invest 98 1996 2572 2579
22. 2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway J Biol Chem 277 2002 30271 30282
23. H.E. Van Wart, and H. Birkedal-Hansen The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family Proc Natl Acad Sci 87 1990 5578 5582
24. B. Halliwell, and J.M. Gutteridge The importance of free radicals and catalytic metal ions in human diseases Mol Aspects Med 8 1985 89 193
25. J. van Horssen, G. Schreibelt, L. Bo, L. Montagne, B. Drukarch, and F.L. van Muiswinkel NAD(P)H:quinine oxidoreductase 1 expression in multiple sclerosis lesions Free Radic Biol Med 41 2006 311 317
26. T.L. Deem, and J.M. Cook-Mills Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species Blood 104 2004 2385 2393
27. A. Ilhan, O. Akyol, A. Gurel, F. Armutcu, M. Iraz, and E. Oztas Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats Free Radic Boil Med 37 2004 386 394
28. E.R. Banerjee, and W.R. Henderson Defining the molecular role of gp91phox in the immune manifestation of acute allergic asthma using a preclinical murine model Clin Mol Allergy 10 2012 2 10.1186/1476-7961-10-2
29. K.Z. Matalka, M.F. Tutunji, M. Abu-Baker, and Y. Abu-Baker Measurement of protein cytokines in tissue extracts by enzyme-linked immunosorbent assays: application to lipopolysaccharide-induced differential milieu of cytokines Neuroendocrinol Lett 26 2005 231 236
30. R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain 129 2006 1953 1971
31. Y. Komiyama, S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, and S. Kakuta IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis J Immunol 177 2006 566 573
32. M.A. Kroenke, T.J. Carlson, A.V. Andjelkovic, and B.M. Segal IL-12 and IL-23-modulated T cells induce distinct types of EE based on histology, CNS profile, and response to cytokine inhibition J Exp Med 205 2008 1535 1541
33. V. Dardalhon, T. Korn, V.K. Kuchroo, and A.C. Anderson Role of Th1 and Th17 cells in organ-specific autoimmunity J Autoimmun 31 2008 252 256
34. E. Cash, A. Minty, P. Ferrara, D. Caput, D. Fraselizi, and O. Rott Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats J Immunol 153 1994 4258 4267
35. E. Bettelli, M.P. Das, E.D. Howard, H.L. Weiner, R.A. Sobel, and V.K. Kuchroo IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice J Immunol 161 1998 3299 3306
36. D.J. Cua, B. Hutchins, D.M. LaFace, S.A. Stohlman, and R.L. Coffman Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis J Immunol 166 2001 602 608
37. E. Butti, A. Bergami, A. Recchia, E. Brambilla, U. Del Carro, and S. Amadio IL-4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis Gene Ther 15 2008 504 515
38. V.S. Ossovskaya, and N.W. Bunnett Protease-activated receptors: contribution to physiology and disease Physiol Rev 84 2004 579 621
39. S. Agrawal, P. Anderson, M. Durbeej, N. van Rooijen, F. Ivars, and G. Opdenakker Dystroglycan is selectively cleaved at the parenchymal basement membrane at the parenchymal sites of leukocyte extravasation in experimental autoimmune encephalomyelitis J Exp Med 203 2006 1007 1019
40. G.A. Rosenberg Matrix metalloproteinases in neuroinflammation Glia 39 2002 279 291
41. M.E. Duncan, J.P. Richardson, G.I. Murray, W.T. Melvin, and J.E. Fothergill Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form Eur J Biochem 258 1998 37 43
42. S. Chandler, R. Coates, A. Gearing, J. Lury, G. Wells, and E. Bone Matrix metalloproteinases degrade myelin basic protein Neurosci Lett 15 1995 223 226
43. K. Gijbels, P. Proost, S. Masure, H. Carton, A. Billiau, and G. Opdenakker Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein J Neurosci Res 36 1993 432 440
44. W.W. Chan l-Leucinethiol - a potent inhibitor of leucine aminopeptidase Biochem Biophys Res Commun 116 1983 297 302
45. D.S. Pickering, M.V. Krishna, D.C. Miller, and W.W. Chan Structural requirements for specific inhibition of microsomal aminopeptidase by mercaptoamines Arch Biochem Biophys 239 1985 368 374
46. T.D. Ocain, and D.H. Rich l-Lysinethiol: a subnanomolar inhibitor of aminopeptidase B Biochem Biophys Res Commun 145 1987 1038 1042
47. M.L. Cuzner, D. Gveric, C. Strand, A.J. Loughlin, L. Paemen, and G. Opdenakker The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution J Neuropathol Exp Neurol 55 1996 1194 1204
48. G.A. Upadhya, and S.M. Strasberg Glutathione, lactobionate, and histidine: cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions Hepatology 31 2000 1115 1122
49. M. Emara, and P.Y. Cheung Inhibition of sulfur compounds and antioxidants on MMP-2 and -9 at the activity level found during neonatal hypoxia-reoxygenation Eur J Pharmacol 544 2006 168 173
50. B. Nagai Studies on the mechanism of metabolic acidosis observed in the children treated with anticonvulsants Hokkaido Igaku Zasshi 57 1982 706 721
51. M.E. Smith Neutral protease activity in lymphocytes of Lewis rats acute experimental allergic encephalomyelitis Neurochem Res 4 1979 689 702
52. C.F. Brosnan, W. Cammer, W.T. Norton, and B.R. Bloom Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis Nature 285 1980 235 237
53. S. Koch, C.M. Volkmar, V. Kolb-Bachofen, H.G. Korth, M. Kirsch, and A.H.C. Horn A new redox-dependent mechanism of MMP-1 activity control compromising reduced low-molecular-weight thils and oxidizing radicals J Mol Med 87 2009 261 272
54. M. Artur, D. Marcin, P.D. John, and K. Pawel Metallo-aminopeptidase inhibitors Biochimie 92 2010 1509 1529
55. W.T. Lowther, and B.W. Matthews Metalloaminopeptidases: common functional themes in disparate structural surroundings Chem Rev 102 2002 4581 4608
56. R.A. Rudick Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications J Neuropatholmol 21 2001 279 283
57. A. Boissy, and R.J. Fox Current treatment options in multiple sclerosis Curr Treat Options Neurol 9 2007 176 186
58. T.M. Jenkins, Z. Khaleeli, and A.J. Thompson Diagnosis and management of primary progressive multiple sclerosis Minerva Med 99 2008 141 155
59. R. Rudick, and A. Sandrock Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS Expert Rev Neurother 4 2004 571 580
60. M.R. Ann, and R.A. Rudick Drug insight: interferon treatment in multiple sclerosis Nat Clin Pract Neurol 2 2006 34 44
61. R.A. Rudick Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease Alzheimers Dement 2 2006 143 146
62. R.A. Bermel, and R.A. Rudick Interferon-beta treatment for multiple sclerosis Neurotherapeutics 4 2007 633 646
63. E. Le Page, E. Leray, G. Taurin, M. Coustans, J. Chaperon, and S.P. Morrissey Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients J Neurol Neurosurg Psychiatry 79 2008 52 56
64. L.D. Kandagaddala, M.J. Kang, B.C. Chung, T.A. Patterson, and O.S. Kwon Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice Exp Toxicol Pathol 64 2012 109 114
65. A. Szklarczyk, J. Lapinska, M. Rylski, R.D. McKay, and L. Kaczmarek Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus J Neurosci 22 2002 920 930
66. S.H. Koh, D.I. Chang, H.T. Kim, J. Kim, M.H. Kim, and K.S. Kim Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model Toxicology 214 2005 131 139
67. X. Cao, X. Dai, L.M. Parker, and D.L. Kreulen Differential regulation of NADPH oxidase in sympathetic and sensory ganglia in deoxycorticosterone acetate salt hypertension Hypertension 50 2007 663 671
68. R. Gold, H.P. Hartung, and K.V. Toyka Animal models for autoimmune demyelinating disorders of the nervous system Mol Med Today 6 2000 88 91
69. D.S. Skundric Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective Curr Neurovasc Res 2 2005 349 362
70. L. Steinman, and S.S. Zamvil Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis Trends Immunol 26 2005 565 571
71. C.B. Basbaum, and Z. Werb Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface Curr Opin Cell Biol 8 1996 731 738
72. H. Birkedal-Hansen Proteolytic remodeling of extracellular matrix Curr Opin Cell Biol 7 1995 728 735
73. T.E. Cawston Proteinases and inhibitors Br Med Bull 51 1995 385 401
74. C. Ries, and P.E. Petrides Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease Biol Chem 376 1995 345 355
75. D. Jean-Michel, and F. Helmut The role of cytokines and their inhibitors in arthritis Baillieres Clin Rheumatol 6 1992 485 516
76. H.S. Panitch, R.L. Hirsch, A.S. Haley, and K.P. Johnson Exacerbations of multiple sclerosis in patients treated with gamma interferon Lancet 1 1987 893 895
77. A.E. Lovett-Racke, A.E. Rocchini, J. Choy, S.C. Northrop, R.Z. Hussain, and R.B. Ratts Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes Immunity 21 2004 719 731
78. J.E. de Vries Immunosuppressive and anti-inflammatory properties of interleukin 10 Ann Med 27 1995 537 541
79. R. de Waal Malefyt, J. Abrams, B. Bennett, C.G. Figdor, and J.E. de Vries Interleukin (IL)-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes J Exp Med 174 1991 1209 1220
80. K.W. Moore, K.W. Moore, R. de Waal Malefyt, R.L. Coffman, and A. O'Garra Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol 19 2001 683 765
81. T.R. Mosmann Properties and functions of interleukin-10 Adv Immunol 56 1994 1 26
82. Q. Liya, and T.C. Fulton NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegenration J Neuroinflammation 9 2012 5 10.1186/1742-2094-9-5
83. H.Y. Song, M.J. Sung, W.Y. Seo, A.R. Goh, J.K. Lee, and Y.S. Bae Nox-2 based NADPH oxidase mediates HIV-1 Tat-induced up-regulation of VCAM-1/ICAM-1 and subsequent monocyte adhesion in human astrocytes Free Radic Biol Med 50 2011 576 584